Mureva and Siemens Healthineers Sign U.S. Co-Marketing Agreement

Mureva Phototherapy and Siemens Healthineers have entered into a co-marketing agreement for the United States market. This collaboration is set to broaden access to Mureva, identified as the first FDA-authorized intraoral phototherapy device for treating radiation-induced oral mucositis (OM).

The agreement facilitates Siemens Healthineers introducing the Mureva treatment to radiation oncology practices across the U.S. The Mureva device received FDA De Novo authorization in 2025, establishing a new Class II classification for intraoral phototherapy devices. It had previously been granted FDA Breakthrough Device Designation.

Oral mucositis is a common and often debilitating side effect for patients undergoing radiation therapy for head and neck cancers. It can impair the ability to eat and swallow, potentially necessitating feeding tubes, disrupting treatment, and diminishing quality of life. Current global guidelines from MASCC/ISOO recommend photobiomodulation (PBM) for the prevention of OM, but practical implementation has been a challenge.

Mureva is designed to make guideline-recommended PBM feasible within existing radiation oncology workflows. The device delivers a 10-minute treatment using two soft, flexible intraoral mouthpieces for daily use. Siemens Healthineers stated that the partnership intends to improve both clinical outcomes and the patient experience.

Under the terms of the agreement, the companies will coordinate customer education, sales enablement, digital promotion, and engagement at industry events. Radiation oncology teams interested in the Mureva treatment can contact their local Siemens Healthineers representative for more information.